Imunon Inc (IMNN)

Currency in USD
2.8000
0.0000(0.00%)
Closed·
IMNN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.76002.9500
52 wk Range
2.520041.2174
Key Statistics
Prev. Close
2.8
Open
2.76
Day's Range
2.76-2.95
52 wk Range
2.52-41.2174
Volume
56.18K
Average Volume (3m)
89.15K
1-Year Change
-74.7153%
Book Value / Share
2.08
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMNN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.2000
Upside
+585.71%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Imunon Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 19.2000
(+585.71% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy10.00+257.14%-New Coverage17/04/2026
H.C. Wainwright
Buy25.00+792.86%14.00Maintain06/02/2026
Brookline Capital Markets
Buy16.00+471.43%21.00Maintain07/01/2026
H.C. Wainwright
Buy14.00+400.00%-Maintain20/06/2025

Imunon Inc Earnings Call Summary for Q4/2025

  • Imunon reported 22% improvement in net loss to $14.5M ($6.83/share) vs $18.6M in 2024, driven by disciplined cost management and R&D reductions.
  • R&D expenses fell to $7.8M following OVATION 2 study completion; company holds $8.8M cash with runway extending into H2 2026.
  • Company actively seeking strategic financing for pivotal OVATION 3 trial; OVATION 2 results showed promising overall survival data for ovarian cancer.
  • Stock trades near 52-week low at $2.88 (-79% YoY) with $9.86M market cap; analysts maintain Strong Buy rating with $12-$33 price targets.
  • Management expressed confidence in IMNN-001's potential despite cash burn concerns; clinical success critical for future funding and regulatory approvals.
Last Updated: 01/04/2026, 03:10 am
Read Full Transcript

Earnings

Latest Release
31/03/2026
EPS / Forecast
-1.45 / -0.23
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMNN Income Statement

Compare IMNN to Peers and Sector

Metrics to compare
IMNN
Peers
Sector
Relationship
P/E Ratio
−0.8x−1.6x−0.5x
PEG Ratio
−0.01−0.020.00
Price/Book
1.6x1.0x2.6x
Price / LTM Sales
-11.9x3.3x
Upside (Analyst Target)
-111.6%47.1%
Fair Value Upside
Unlock15.5%6.2%Unlock

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
83.55K2.13%233.94K
Other Institutional Investors
839.73K21.41%2.35M
Public Companies & Retail Investors
3.00M76.46%8.40M
Total
3.92M100.00%10.98M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Armistice Capital Master Fund Ltd.8.92%349,917980
Armistice Capital LLC8.92%349,917980

People Also Watch

2.510
CDXS
-5.99%
7.33
ELPW
+65.84%
2.160
AIFF
-4.85%
1.5700
GERN
-0.63%
0.304
BURU
+1.67%

FAQ

What Is the Imunon (IMNN) Stock Price Today?

The Imunon stock price today is 2.8000 USD.

What Stock Exchange Does Imunon Trade On?

Imunon is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Imunon?

The stock symbol for Imunon is "IMNN."

What Is the Imunon Market Cap?

As of today, Imunon market cap is 11.1800M USD.

What Is Imunon's Earnings Per Share (TTM)?

The Imunon EPS (TTM) is -6.8265.

When Is the Next Imunon Earnings Date?

Imunon will release its next earnings report on 13/11/2025.

From a Technical Analysis Perspective, Is IMNN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Imunon Stock Split?

Imunon has split 5 times.

How Many Employees Does Imunon Have?

Imunon has 25 employees.

What is the current trading status of Imunon (IMNN)?

As of 05/05/2026, Imunon (IMNN) is trading at a price of 2.8000 USD, with a previous close of 2.8000 USD. The stock has fluctuated within a day range of 2.7600 USD to 2.9500 USD, while its 52-week range spans from 2.5200 USD to 41.2174 USD.

What Is Imunon (IMNN) Price Target According to Analysts?

The average 12-month price target for Imunon is 19.2000 USD, with a high estimate of 33 USD and a low estimate of 10 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +585.71% Upside potential.

What Is the IMNN Premarket Price?

IMNN's last pre-market stock price is 2.8690 USD. The pre-market share volume is 60.0000, and the stock has decreased by 0.0690, or 2.4600%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.